Company Overview and News
This is the second month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $1,300.03.
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.
msb_8-K_20180426 UNITED STATES
msb_CurrentFolio_10K Table of Contents
This is the first month I have officially tracked dividend income (in an article) in Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $883.70.
This is the 5th month I have officially tracked dividend income and it was slightly above expectations with a total of $929.59 of dividends received.
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
By all evidence, it looks like the U.S. economy and the global economy are finally recovering — without the aid of central banks at this point.
This is the 4th month I have officially tracked dividend income and it was the strongest month yet with a total of $1271.50 of dividends received.
Mesabi Trust has recently bounced back, with current fiscal year revenue roughly triple that of last years.
With a low valuation and steady growth for iron ore, the Mesabi Trust should thrive over many years.
I think we can all agree that we've forgotten what volatility looks like because of the ever-increasing valuations associated with equities.
This is the third month I have officially tracked dividend income and it was another strong month with a total of $1020.98 of dividends received.
Mail Stop 3561 December 20, 2017 Via E-mail Jeffrey Schoenfeld Mesabi Trust c/o Deutsche Bank Trust Company Americas Trust & Agency Services 60 Wall Street, 16 th Floor New York, New York 10005 Re: Mesabi Trust Form 10-K for Fiscal Year Ended January 31, 2017 Filed April 14, 2017 File No. 001-04488 Dear Mr. Schoenfeld: We have reviewed your filing and have the following comment.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET